Seven years ago, Lovepreet K. Mann was standing at a crosswalk in Salt Lake City with her husband and colleague, Dr. Ramesha Papanna. They had been testing an underwater glue for fetal surgery, and a thought suddenly occurred to her. There, on the street in Utah, the couple began a discussion that would ultimately lead to a patch made from human umbilical cord. Today, it is being used to help repair spina bifida in babies before they’re even born.
A “super C-section”
Spina bifida is a birth defect characterized by an incomplete closing of the bones and membranes surrounding the spinal cord. In most cases, tissues and nerves are exposed in an opening along several vertebrae in the baby’s back, making him or her highly susceptible to life-threatening infections and sometimes triggering complete paralysis of the legs as well as bladder incontinence and a range of cognitive difficulties. The condition is typically detected in a pregnant woman’s 20-week anatomy scan, during which time the ultrasound tech identifies either a lemon-shaped head or a “banana sign,” both caused by pulls in the cranial area from the spinal malformation.
For decades, the standard treatment has included postnatal surgery, but sentiments shifted after the groundbreaking NIH-funded MOMS Trial (Management of Myelomeningocele Study) initiated in 2003, in which standard repair results were benchmarked against more than 90 fetal repair cases. The results spoke volumes. Babies who underwent fetal repair were much less likely to need a ventricular shunt for hydrocephalus. Furthermore, twice as many children from the fetal surgery group were able to walk without crutches at 30 months of age, compared to those who received the surgery after birth.
Not all patients qualify for the highly specialized, extremely complex procedure, which involves either pulling the skin together or stitching a patch directly onto the spina bifida site of the fetus while it is still in the mother’s womb. Likened to a “super C-section,” the intricate series of surgical steps (making an incision in the mother, protecting the placenta, opening up the amniotic sac, preserving the fluid, performing the repair through a tiny three-inch by four-inch window in the uterus, replacing the fluid, closing the uterus and then the mother layer by layer) is also not without risk. Most babies who undergo fetal surgery will be born prematurely. There is potential for post-surgical complications and infections. There is the risk of death. And, until Mann, a research instructor in the Department of Obstetrics, Gynecology and Reproductive Sciences at McGovern Medical School, thought of using the regenerative material she and Papanna had been studying to patch the site, there was the likely possibility of scar tissue formation, which meant further injury to the spinal cord as the child grew and developed.
Originally, Papanna, the principal investigator and an assistant professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at McGovern Medical School at The University of Texas Health Science Center at Houston and a maternal-fetal medicine specialist at The Fetal Center at Children’s Memorial Hermann Hospital, was interested in using amniotic membrane from the placenta to seal fetal membranes—the layers of the amniotic sac—after surgeries in utero. He and Mann flew to Miami to meet with expert ophthalmologist Scheffer C.G. Tseng, M.D., Ph.D., who was using a human amniotic membrane patch to repair corneas. After spending a week in his center, the two were even more impressed at its regenerative properties.
What makes the material so “magical,” as Papanna puts it, is a compound called heavy chain hyaluronic acid/pentraxin3, which initiates natural regeneration of the tissues at the repair site, rather than healing by scar formation. The distinction is important in spina bifida repair since one creates a healthy, biologically compatible environment while the other often leads to scarring of the spinal cord to the repair site. This can lead to loss of bladder and motor function later in life. If scarring occurs, further surgeries are required to remove the scar tissue and protect the spine.
“The molecule is the same one that is present around the egg of every woman who ovulates every month, in the lining of the womb and the placenta. This is essential to maintain normal reproductive function,” Papanna said. “Nature has created a solution, and we have harnessed it to our benefit.”
But this wasn’t the fairytale ending Papanna and Mann had hoped for. Despite its phenomenal healing properties, the amniotic membrane patch was paper-thin and flimsy, making it difficult to work with.
“If the site gets infected, the baby dies,” explained Kenneth Moise, M.D., director of the Fetal Intervention Fellowship Program at McGovern Medical School and co-director of The Fetal Center at Children’s Memorial Hermann Hospital. “It’s covering the spinal cord, so it has to be a watertight seal—CSF [cerebrospinal fluid] can’t leak out and infections can’t come in.”
Unfortunately, every time Papanna practiced his stitches on the delicate material, it tore. So he looked to the umbilical cord, which contains the same “magical” molecules as the amniotic membrane, but is thicker and far more pliable.
“It was so obvious,” Papanna said. “The umbilical cord has the same regenerative properties.”
Mann and Papanna contacted Tseng, who created a new patch and sent it back to them for testing. After suturing multiple chicken breasts and injecting blue dye as a proxy for cerebral spinal fluid, Papanna and Mann were satisfied that it could provide the watertight seal necessary for spina bifida repair. Papanna’s lab studied its performance in animal models and he was granted approval from the FDA for clinical use in three cases. He and a team of surgeons including Moise, Kuojen Tsao, M.D., co-director of the Fetal Center at Children’s Memorial Hermann Hospital and an associate professor at McGovern Medical School’s Department of Pediatric Surgery, and pediatric neurosurgeon Stephen Fletcher, D.O., an associate professor in McGovern Medical School’s Department of Pediatric Surgery, performed the first surgery in July 2015. A second case was performed a few months later, and the results of the two surgeries were published in Obstetrics and Gynecology in July of this year.
So far, they have been success stories. In both cases, the surgeries went well and the babies were born at 37 and a half weeks, just three weeks shy of full term. At birth, the patch was still in place and there were no signs of leakage or fluid inside. Moreover, both babies retained lower limb function as well as normal bowel movements. The one peculiarity was that, at birth, the site had not yet regenerated—it was semi-translucent, and when Papanna tapped the baby’s head, he could see the cerebrospinal fluid underneath the patch. Within a few weeks, however, the skin grew into the patch exactly as expected.
“Every day you could watch the blood vessels and the tissues grow closer together,” Papanna said. “It was incredible.”
A third case was completed and as the months pass, all three babies continue to exhibit normal leg movement and bladder control and no need for further repair. The true test will come with time, but already the patch is showing promise as the next big advancement in fetal surgery: whereas the MOMS Trial demonstrated that fetal surgery could vastly improve outcomes in mobility and neurological development, this patch could take the procedure a step further, resulting in an even more improved outcome for children with spina bifida. Perhaps, in the future, there will be no more need for surgical revisions, no additional repairs, few if any symptoms. An entirely normal childhood.
“People are trying stem cells and different ‘off the shelf’ patches, but this patch is doing more than any of the others,” Mann said. “It’s helping with regeneration of existing skin. It’s creating organized growth of tissues, and the body doesn’t reject it. Even more, its source is abundant since the umbilical cord from every pregnancy could produce a new patch.”
“Where are all the other babies?”
Currently, Papanna and his team are pursuing additional clinical studies and working to expand their approval from the FDA for more cases. They hope to apply the patch using fetoscopic repair techniques, which would reduce surgical risks to both the mother and the baby. Ultimately, they also aim to create a standard of care for babies diagnosed with spina bifida.
“Right now, the techniques being used to close the spina bifida are all over the map, and the outcomes vary considerably,” said Moise, who recently returned from Botswana where the International Fetal Medicine and Surgery Society convened for their annual conference.
“Nobody has a standard way of treating this, but we all agree that whatever patches or fetoscopic approach we use, the outcomes should be judged against the MOMS Trial. We all want to develop something better than what we’re already doing.”
Moise expects that a standard of care, as well as increasingly positive outcomes, will also encourage OBGYNs to refer more of their patients to fetal centers for counseling.
“We should be three times busier than we are,” Moise said. “There are over 200 babies born in Texas every year with spina bifida. Two hundred. And we might do eight or 10 cases a year. Where are all the other babies?”
Even more, he hopes standardizing treatment will change the climate surrounding fetal repair surgery worldwide. Currently, there are only a handful of sites outside the U.S. that do fetal surgical repairs. According to Moise, many countries, including most of Western Europe, consider a spina bifida diagnosis the equivalent of an unviable pregnancy.
“They think we’re crazy to do what we do,” Moise said.
#Immunotherapy has shown remarkable success, but it doesn’t work for everyone and results can vary.That’s why our researchers are conducting #clinicaltrials that combine immunotherapy with other therapies: https://t.co/klJw9jdvG8 #endcancer
@thadroher Thank you, Thad. We are grateful for your support.
Bikers honor Vets: ‘Run for the Wall’ stopping in Longview, TX https://t.co/miAB7a2A9b via @KLTV7
U.S. Department of Veterans AffairsVeteransAffairs
Today’s #VeteranOfTheDay is Marine Corps Veteran Brad Pesek. Brad served for 20 years and made multiple deployments during Operation Iraqi Freedom.Born in Saint Louis, Missouri, Brad enlisted with the United States Marine Corps in June 1998. He attended boot camp at the Marine Corps Recruit Depot in San Diego, California and infantry training at Camp Pendleton, California.After completing his training, Brad was assigned to Bravo Company, 1st Battalion, 3rd Marines stationed at Marine Corps Base Hawaii. There, Brad was deployed twice to Okinawa, Japan as part of the Unit Deployment Program.Following his time at Marine Corps Base Hawaii, Brad was assigned to the School of Infantry at Camp Pendleton, California. There, he served as a Marine combat instructor and reached the rank of sergeant.After his time serving as an instructor at Camp Pendleton, Brad was assigned to 3rd Battalion, 5th Marines, where he served as a squad leader, machine gun section leader, mortar section leader, and platoon sergeant. During his time with 3/5, Brad was deployed twice to Iraq in support of Operation Iraqi Freedom, once in January 2006 and once in September 2007.Following his time with 3/5, Brad returned to the School of Infantry at Camp Pendleton for a second tour as a Marine Combat Instructor. There, Brad was assigned to the Infantry Squad Leader Course, where he served as a squad instructor, assistant chief instructor, and later chief instructor. By December 2010, Brad had earned the rank of gunnery sergeant.Upon completing his tour as a Marine combat instructor, Brad was assigned to 2nd Battalion, 3rd Marines stationed at Marine Corps Base Hawaii. There, he served as a weapons platoon sergeant and company gunnery sergeant. During this time, Brad deployed twice in support of the Unit Deployment Program, serving in Darwin, Australia in 2012 for the first Marine Rotational Force-Darwin and in Okinawa, Japan in 2013.Following his time with 2/3, Brad began working as the assistant training chief for the 1st Marines, G-3 Training Section at Camp Pendleton, California. In January 2015, Brad was promoted to first sergeant and assigned as company first sergeant of the 1st Marine Raider Support Battalion.Brad retired from the Marine Corps in February 2019 after 20 years of service. Throughout his long service, Brad earned the Navy and Marine Corps Commendation Medal, the Navy and Marine Corps Achievement Medal with Combat Distinguishing Device, the Combat Action Ribbon, and the Meritorious Service Medal.Thank you for your service, Brad!
University of Houston@UHouston
RT @FrontierFiesta: 📸LIVE right now at #FrontierFiesta! https://t.co/PwwxUeSu3V
Today’s #VeteranOfTheDay is Marine Corps Veteran Brad Pesek. Brad served for 20 years and made multiple #OIF deployments https://t.co/JDJk73aIjb
University of Houston@UHouston
RT @MarchMadnessTV: Houston is on a mission to make the city proud.Kelvin Sampson has fostered a family atmosphere all around @UHCougarMB…
See how Melanie McNeal stays fit in this week's healthy habits post. https://t.co/YDURUq6Ii5 #healthy #habits
Baylor College of MedicineBaylorCollegeOfMedicine
For decades, the link between education and healthcare has been the driving concept behind development of programs to improve community health at Baylor College of Medicine. Learn more about our initiatives: https://bit.ly/2t4NynV #education #community
SECCA Presents Staged Reading of WWII Pacific Engagement Veterans’ Stories https://t.co/rFBKFyDPpc via @yesweekly
U.S. Department of Veterans AffairsVeteransAffairs
Happy Birthday, Frank!
Families with children of all abilities are invited to the annual Texas Children’s West Campus Family Fun Run on Saturday, April 6. Register your family at https://t.co/kj6xpuWTSJ
“People who carry hereditary mutations do not necessarily get cancer, but their risk of developing the disease at some point during their lifetime is higher than average,” says our @KarenLuMD.How we help those with genetic risk of #cancer: https://t.co/W6Rf3WPl9r #endcancer
MD Anderson Cancer CenterMDAnderson
"I was really worried about the recovery," recalls Bridgette Fleming, who underwent laparoscopic colon resection in late March 2018 to treat her colon cancer. "But I was surprised that even after a major abdominal surgery, I only had to use the pain pump twice a day for a few days."Here's how our Enhanced Recovery Program is helping patients like Bridgette rebound faster after surgery. #endcancer
A candlelight vigil was held March 20 commemorating the 50 lives lost in the New Zealand mosque attacks.On March 27, Rice will host an Islamophobia teach-in all day in solidarity with the Muslim community: https://t.co/ugA11IDcGz https://t.co/8siFEZshmc